• Biocytogen Pharmaceuticals will hold its third extraordinary general meeting in Beijing on Sept. 16, 2026.
• Shareholders will vote on changing the implementation method for a proceeds-funded project tied to its A-share IPO.
• The plan shifts building construction from outright payment to a lease model, with lease payments funded from the company’s own cash.
• RMB 120 million already paid to the contractor is set to be refunded into the IPO proceeds account.
• RMB 254.11 million of proceeds would be redirected to renovation works and equipment procurement for the same project.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biocytogen Pharmaceuticals Beijing Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260827-12301716), on August 27, 2026, and is solely responsible for the information contained therein.